ArticleMolecular oncology2021
Cancer outcomes research-a European challenge: measures of the cancer burden.
Article in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Effect of structured nursing care on treatment tolerance and quality of life in patients with esophageal cancer undergoing radiotherapy: a retrospective cohort study.Frontiers in oncology · 2026Article
- Nutritional Status of Patients with Neoplasms Undergoing Ambulatory Chemotherapy and Associated Factors.Nutrients · 2025Article
- Nano-enabled strategies for targeted immunotherapy in gastrointestinal cancers.Frontiers in immunology · 2025Review
- Article
- Avoiding lead-time bias by estimating stage-specific proportions of cancer and non-cancer deaths.Cancer causes & control : CCC · 2024Article
- Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems.Heliyon · 2024Article
- Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects.Frontiers in immunology · 2024Review
- Overall and Cervical Cancer Survival in Patients With and Without Mental Disorders.JAMA network open · 2023Article
- ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023.JCO global oncology · 2023Article
- Engaging European society at the forefront of cancer research and care: How discussions at the 5Molecular oncology · 2023Article
- Increased incidence and improved survival in endometrial cancer in Sweden 1960-2014: a population-based registry survey.BMC cancer · 2023Article
- Identifying Priorities and Needs to Improve Oncology Research in the Gaza Strip, Palestine.Journal of multidisciplinary healthcare · 2023Article
- Time Trends for Incidence and Net Survival of Cervical Cancer in Sweden 1960-2014-A Nationwide Population-Based Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Recombinant jurkat cells (HMGN2-T cells) secrete cytokines and inhibit the growth of tumor cells.Journal of molecular histology · 2022Article
- Cancer outcome research - a European challenge Part II: Opportunities and priorities.Molecular oncology · 2022Review
- Post-traumatic growth in cancer survivors: What is its extent and what are important determinants?International journal of clinical and health psychology : IJCHPArticle
- Trends in long-term cancer survival in Cali, Colombia: 1998-2017.Colombia medica (Cali, Colombia)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a mission that aims to improve cancer control throughout Europe, the European Academy of Cancer Sciences has defined two key indicators of progress: within one to two decades, overall cancer-specific 10-year survival should reach 75%, and in each country, overall cancer mortality rates should be convincingly declining. To lay the ground for assessment of progress and to promote cancer outcomes research in general, we have reviewed the most common population-based measures of the cancer burden. We emphasize the complexities and complementary approaches to measure cancer survival and the novel opportunities for improved assessment of quality of life. We propose that: incidence and mortality rates are standardized to the European population; net survival is used as the measure of prognosis but with proper adjustments for confounding when temporal trends in overall cancer survival are assessed; and cancer-specific quality of life is measured by a combination of existing questionnaires and utilizes emerging communication technologies. We conclude that all measures are important and that a meaningful interpretation also requires a deep understanding of the larger clinical and public health context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.